Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

This HUGE NEWS is great for shareholders of Bristol Myers Squibb, which has just received FDA approval for their KarXT for schizophrenia. Once again, our illustrious CEO, Christopher U. Missling, PhD, MS, MBA, BSr, is way behind the curve in terms of development of 3-71 for schizophrenia and has lost yet another big market opportunity (schizophrenia estimated at $8.2 billion annually) to a faster, more nimble competitor with much deeper pockets.

This is absolutely not good news for Anavex or its suffering shareholders. To pretend that it is good news for Anavex is beyond ridiculous (or perhaps simply delusional).